Simultaneous determination of anti-diabetic drugs

Anti-Diabetic Drugs

Diabetes mellitus affects up to 6% of the UK population, although it is estimated that around half of these individuals remain undiagnosed. It occurs equally in both sexes but varies with age and race. The ethnic group at highest risk is the Pima Indians in North America with a 50% prevalence of diabetes. Other high-risk groups include the Afro-Caribbean and Asian populations, who are at four t...

Cardiovascular safety of anti-diabetic drugs.

Cardiovascular disease is the leading cause of morbidity and mortality among patients with diabetes, underscoring the importance of choosing anti-diabetic drugs that do not increase cardiovascular risk but might reduce the risk of cardiovascular events. Most type 2 diabetic patients die from cardiovascular causes despite the beneficial effects of blood pressure (BP) and lipid-lowering medicatio...

Medicinal Chemistry of Novel Anti-Diabetic Drugs

Diabetes mellitus is a common metabolic disorder affecting millions of people worldwide. The prevalence of this chronic, endocrine condition continues to grow, from a world-wide prevalence of 221 million in 2010 to a projected 300 million in 2030 [1, 2]. The majority (~90%) of patients suffering from diabetes mellitus have type 2 while about 10% have type 1. Type 1 diabetes is caused by immunol...

Pharmacogenetics for T2DM and Anti-Diabetic Drugs

Vascular failure and recent anti-diabetic drugs

Type 2 diabetes mellitus (T2DM) is highly prevalent and is a critical risk factor for cardiovascular (CV) disease, increasing both morbidity and mortality. T2DM is one of the most important classical CV risk factors that promote atherosclerosis. Therefore, it is important for both patients with T2DM and their doctors to identify vascular dysfunction at an early stage of atherosclerosis. Recentl...